Narrow search
Showing 1 - 10 of 81
Cover Image
Pharmaceutical innovation, longevity, and medical expenditure in Greece, 1995 - 2010
Lichtenberg, Frank - 2015
death), hospital utilization, and medical expenditure in Greece during the period 1995 - 2010. The estimates indicate that … increases in the number of hospital days. Real per capita pharmaceutical expenditure increased rapidly during this period, but … 62% of the increase in pharmaceutical expenditure was offset by a reduction in hospital expenditure attributable to …
Persistent link: https://www.econbiz.de/10010473542
Cover Image
Private versus social incentives for pharmaceutical innovation
González, Paula; Macho-Stadler, Inés; … - 2015
We provide a theoretical framework to contribute to the current debate regarding the tendency of pharmaceutical companies to direct their R&D toward marketing products that are "follow-on" drugs of already existing drugs, rather than toward the development of breakthrough drugs. We construct a...
Persistent link: https://www.econbiz.de/10011406575
Cover Image
The impact of R&D cooperations on drug variety offered on the market : evidence from the pharmaceutical industry
Banerjee, Tannista; Siebert, Ralph - 2014
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
Cover Image
The effect of intellectual property rights on domestic innovation in the pharmaceutical sector
Gamba, Simona - 2016
This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of 74 countries. The identification strategy exploits the different timing across countries of two sets of IPR reforms. Domestic innovation is measured as citation-weighted...
Persistent link: https://www.econbiz.de/10011509446
Cover Image
Dynamic mergers effects on R&D investments and drug development across research phases in the pharmaceutical industry
Siebert, Ralph; Tian, Zhili - 2020
Pharmaceutical firms spend increasing amounts in mergers and acquisitions (M&As), which raises the question of whether sufficient investment is left after mergers to further develop firms' internal drug development capability. We evaluate the effects of M&As on firms' post-merger R&D...
Persistent link: https://www.econbiz.de/10012219372
Cover Image
Dynamic effects of licensing and knowledge transfer across research stages : evidence from the pharmaceutical industry
Tian, Zhili; Siebert, Ralph - 2020
In the pharmaceutical industry, firms frequently engage in licensing agreements to overcome innovation challenges and keep up with the pace of developing new drugs. Licensing helps firms jointly develop new drugs and acquire external knowledge, which helps improve their internal drug...
Persistent link: https://www.econbiz.de/10012219514
Cover Image
A probability approach to pharmaceutical demand and price setting : does the identity of the third-party payer matters for prescribing doctors?
Dalen, Dag Morten; Locatelli Biey, Marilena; Sorisio, Enrico - 2011
national insurance. -- pharmaceuticals ; discrete choice model ; funding-schemes …
Persistent link: https://www.econbiz.de/10009377790
Cover Image
Do cost-sharing and entry deregulation curb pharmaceutical Innovation?
Grossmann, Volker - 2011
deregulation may lead to quality-improvements of pharmaceuticals, despite reducing price-setting power of pharmaceutical companies …
Persistent link: https://www.econbiz.de/10009124148
Cover Image
Response to Baker and Fugh-Berman's critique of my paper, "Why has longevity increased more in some states than in others?"
Lichtenberg, Frank R. - 2009
Dean Baker and Adriane Fugh-Berman have published a critique of a study I performed in 2007, entitled "Why has longevity increased more in some states than in others?ʺ One of the conclusions I drew from that study was that medical innovation accounts for a substantial portion of recent...
Persistent link: https://www.econbiz.de/10003861794
Cover Image
Medical innovations and ageing : a health economics perspective
Grossmann, Volker - 2021
surveys empirical evidence on medical R&D incentives, R&D costs of pharmaceuticals, and the cost-effectiveness of health …
Persistent link: https://www.econbiz.de/10012653346